Nuveen AMT-Free Municipal Credit Income Fund (NVG)

I increased exposure to municipal bond CEFs, adding Nuveen AMT-Free Municipal Credit Income Fund and Nuveen Municipal Credit Income Fund for higher yields. NXP remains a core holding for its high quality, low leverage, and investment-grade focus, contrasting with NVG and NZF's higher yield and risk profiles. NVG and NZF deploy over 40% leverage and hold 74–75% investment-grade bonds, with notable exposure to Illinois, Texas, and California.

Nuveen AMT-Free Municipal Credit Income Fund (NYSE: NVG - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $12.72 and traded as high as $13.26. Nuveen AMT-Free Municipal Credit Income Fund shares last traded at $13.22, with a volume

Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injury Completed a U.S. Food and Drug Administration (FDA) Type C meeting in September; FDA confirmed that multiple regulatory routes are available to support approval of NVG-291 as the first pharmacologic treatment for spinal cord injury Completed a US$10 million non-brokered private placement to support an anticipated Nasdaq listing, with participation from both long standing and new mission-driven investors, including SCI Ventures NVG-291-R demonstrated statistically significant functional recovery in U.S. Department of Defense sponsored preclinical models of traumatic hearing loss and peripheral nerve injury, reinforcing NVG-291's broad therapeutic potential Vancouver, British Columbia--(Newsfile Corp. - November 24, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced financial results and provided business updates for the third quarter ended September 30, 2025. "The third quarter represented a continuation of the historic momentum we first articulated in our second quarter shareholder letter.

Nuveen AMT-Free Municipal Credit Income Fund offers a 7.79% yield, monthly distributions, and AMT-free income, appealing to tax-sensitive investors. NVG trades at a 4.85% discount to NAV, below its 10-year average, enhancing its attractiveness for value-focused buyers. The NVG fund's portfolio is diversified across 1,088 holdings, with significant allocations to tax obligation, healthcare, and housing sectors.

Demonstrated significant hearing restoration in blast-induced sensorineural hearing loss models Promoted significant functional recovery and axonal regeneration in peripheral nerve injury models Reinforced NVG-291's broad therapeutic potential with new data across three distinct injury models Vancouver, British Columbia--(Newsfile Corp. - August 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurologic disorders, today announced positive preclinical results of two Department of Defense sponsored studies in models of blast-induced sensorineural hearing loss and peripheral nerve injury, reinforcing the broad therapeutic application of its first and potential best-in-class candidate, NVG-291. Presented at the 2025 Military Health System Research Symposium, the studies show that NVG-291-R, the rodent variant of NVG-291, promoted significant functional recovery in models of blast-induced sensorineural hearing loss and peripheral nerve injury, two debilitating conditions affecting military and civilian populations.

Vancouver, British Columbia--(Newsfile Corp. - July 1, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced that Daniel Mikol, MD, Ph.D., has resigned from his position as Chief Medical Officer in order to pursue new opportunities.

NervGen Pharma's NVG-291 shows promising early trial results for spinal cord injury, especially in restoring hand function, with strong clinical relevance. Despite a narrow pipeline and high cash burn, investor enthusiasm remains high, driven by technical momentum and anticipation of pivotal clinical data. The company targets a neglected market with significant unmet needs, offering high-risk, high-reward potential if NVG-291 succeeds in upcoming trials.

NVG is a closed-end municipal bond fund, leveraging credit and interest rate risk to maximize tax-free income for high-income investors. The fund is AMT-free and targets investors facing high federal income tax rates, but its appeal is limited by its capital return distribution. A significant portion of NVG's distribution is return of capital, not earned income, which raises concerns about sustainability and suitability.

Vancouver, British Columbia--(Newsfile Corp. - May 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that topline results from the chronic cohort of the ongoing Phase 1b/2a study of NVG-291 will be presented as an oral presentation at the 52nd American Spinal Injury Association Annual Scientific Meeting being held June 2-4, 2025 in Scottsdale, AZ. "We are looking forward to completing the data analysis, unblinding the data, and presenting the first results from the chronic cohort in this initial proof-of-concept, double-blind, placebo-controlled clinical trial of NVG-291 in spinal cord injury ("SCI")," stated Daniel Mikol, MD, Ph.D.

Completed enrollment in the chronic cohort and commenced enrollment in the subacute cohort of its Phase 1b/2a clinical trial for lead drug candidate, NVG-291, in spinal cord injury (SCI) Initiated an expanded access protocol for NVG-291 for individuals with SCI who have participated in a NervGen clinical trial and meet specific eligibility criteria Pipeline candidate NVG-300 showing promising activity in preclinical models of ischemic stroke and SCI Vancouver, British Columbia--(Newsfile Corp. - April 3, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today reported its financial and operational results for the full year ended December 31, 2024. "2024 was a very productive year for NervGen as we advanced the clinical development of our lead candidate, NVG-291, in spinal cord injury and delivered on key research activities and business milestones," said Mike Kelly, President and Chief Executive Officer of NervGen Pharma.

Key opinion leaders and company management will discuss the current spinal cord injury treatment landscape and NervGen's Phase 1b/2a clinical trial evaluating NVG-291 in individuals with spinal cord injury Key opinion leaders and company management will discuss the current spinal cord injury treatment landscape and NervGen's Phase 1b/2a clinical trial evaluating NVG-291 in individuals with spinal cord injury

Vancouver, British Columbia--(Newsfile Corp. - February 6, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that the first subject has been enrolled and dosed in the subacute cohort of its Phase 1b/2a proof-of-concept, double-blind, randomized placebo-controlled clinical trial (NCT05965700) evaluating its lead candidate, NVG-291, in individuals with spinal cord injury (SCI). The company previously reported the completion of enrollment of the chronic cohort and announced that results for the chronic cohort are expected in Q2 2025.

Topline data from the chronic cohort is expected in Q2 2025 Institutional Review Board (IRB) protocol amendment changes approved, and screening has been initiated for subacute cohort This news release constitutes a "designated news release" for the purposes of NervGen's prospectus supplement dated December 19, 2024 to its short form base shelf prospectus dated November 25, 2024. Vancouver, British Columbia--(Newsfile Corp. - January 2, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has enrolled the 20th and final subject in the chronic cohort of its Phase 1b/2a proof-of-concept, double-blind, randomized placebo-controlled clinical trial (NCT05965700) evaluating its lead candidate, NVG-291, in individuals with spinal cord injury (SCI).

Several Nuveen municipal bond closed-end funds aggressively raised distributions earlier this year, one of those funds being NVG. NVG's high leverage and potential mixture of lower credit quality exposure offer higher yields, but that does come with increased risks. Despite recent Fed rate cuts, coverage of the distribution is likely to remain weak, this is likely to lead to a mix of tax-free and tax-deferred income classified distributions.

Target enrollment in the chronic cohort close to completion Vancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that target enrollment of the chronic cohort in its Phase 1b/2a proof-of-concept, double-blind, randomized placebo-controlled clinical trial (NCT05965700) for its proprietary investigational lead compound, NVG-291, in individuals with spinal cord injury (SCI) is approaching completion. "We are excited to be near completion of enrollment in the chronic cohort of our Phase 1b/2a study in SCI," said Mike Kelly, NervGen's President & CEO.

Market conditions are very favorable to own long duration and top credit Muni funds, with rate cut expected and a slowing economy. NVG is a top Muni fund with 7.3% tax-exempt yield and 9.4% NAV discount. NVG's high leverage is expected to work well in the rate-declining cycle.